Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

AAD 2024 Insights: What's New In Nail Tumors

AAD 2024

J. Dominguez-Cherit

AAD 2024 Insights: Management of Locally Advanced Basal Cell Carcino…

AAD 2024

V. Patel

AAD 2024 Insights: Immunomodulators in Non-Melanoma Skin Cancer

AAD 2024

V. Patel

Year in Review: Updates in Non-Melanoma Skin Cancers

Dana-Farber Cancer Institute

K. Khaddour

EADV 2023 Insights: Non-Melanoma Skin Cancer Management in Organ Tra…

EADV 2023 Insights

G. Hofbauer

Management of High Risk Squamous Cell Carcinoma

NYU Langone

M. L. Stevenson

Basal Cell Carcinoma: Pathophysiology of the Hedgehog Pathway and In…

Brian Berman

EADV 2024 Insights: Dermatology in Skin of Color Patients - Challeng…

EADV 2024 Insights

N. Benmehidi

ESMO 2023 Insights: "Neoadjuvant Cemiplimab for Stage II to IV CSCC …

Insights from 2023 ESMO Annual Meeting

N. Gross

Neoadjuvant IO: Non-Melanoma Skin Cancer

ImmunoTherapy Bridge 2023

N. Gross

Super Giant Basal Cell Carcinoma: A Comprehensive Systematic Review

Jay Kang

Fred Hutchinson Cancer Center Head & Neck Cancer Updates

Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

C. Rodriguez

Non-Melanoma Skin Cancers

ImmunoTherapy Bridge 2023

P. A. Ascierto

2023 ASCO® Direct Philadelphia: Melanoma Updates

Total Health

M. Orloff

PD-1 Inhibitors for Advanced Basal Cell Carcinoma and Squamous Cell …

Todd Schlesinger

ASCO® 2023 Insights: "To Treat or Not to Treat - Challenging Scenari…

Insights from 2023 ASCO® Annual Meeting

K. Margolin

ESMO 2023 Insights: "Survival Results for Neoadjuvant Cemiplimab in …

ecancer

N. Gross

Clinical Activity of MCLA-158 (Petosemtamab), an IgG1 Bispecific Ant…

AACR 2023 Conference Coverage

E. Cohen

Immunotherapy and Anti-Angiogenic Therapies in HNSCC

Yale Cancer Center

A. Bhatia